Mise en place d'une réserve pilote de vaccins contre les filovirus pour essais cliniques
Titre original de l'avis
Belgium – Research and experimental development services – Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve
Score d'opportunité
Pourquoi ce score ?
Opportunité
70 / 100
Complexité
65 / 100
Facteurs de risque
Rapid deployment of investigational vaccines during outbreaks requires pre-established logistics, regulatory approvals...
Investigational vaccines are subject to evolving EU and international regulations. Changes in clinical trial or manufac...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Informations clés
- Pouvoir adjudicateur
- Health and Digital Executive Agency (HaDEA) , HADEA - Health and Digital Executive Agency
- Pays
- Belgique
- CPV
- 73100000 - Research and experimental development services +1 autres
- Date limite
- Aug 25, 2026
- Valeur estimée
- EUR 16M
Aperçu
Moderate opportunityFaits clés
- EUR 16M estimated value
- Services contract
- 1 lot
- Duration 48 MONTH
- Establish and maintain a reserve of investigational Filovirus vaccines (Ebola Sudan, Ebola Bundibugyo, Marburg) in the EU.
- Ensure rapid deployment of investigational doses during outbreaks subject to conditions.
Afficher le résumé complet
This open tender by the Health and Digital Executive Agency (HaDEA) seeks to establish a pilot EU-based reserve of investigational Filovirus vaccines (against Ebola Sudan, Ebola Bundibugyo, and Marburg) to ensure clinical trial preparedness. The contract involves maintaining and rapidly deploying candidate vaccines during outbreaks. The single lot has an estimated value of €16,000,000 (EU-funded) and a duration of 48 months. Award is based on quality (80%) and price (20%). Submission deadline is 25 August 2026. Key documents and eligibility details are not specified in the provided data.
Risques
Rapid deployment of investigational vaccines during outbreaks requires pre-established logistics, regulatory approvals...
Investigational vaccines are subject to evolving EU and international regulations. Changes in clinical trial or manufac...
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Tenderers must have the capability to manufacture, store, and maintain investigational vaccines under appropriate conditions.
- Rapid deployment mechanism must be in place for outbreak scenarios.
- Compliance with EU regulations and funding requirements (EU4Health programme).
Les exigences peuvent être incomplètes.
Critères d'attribution
Lot 1
Acheteur
Localisation
Brussels, BEL
Site web
Identifiant
HADEA
Activité
General public services
Lots (1)
LOT-0001
Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve
This lot covers the establishment, piloting, and maintenance of an investigational reserve of Filovirus candidate vaccines (SUDV, BDBV, MARV) for rapid deployment in outbreak-associated clinical trials. Tenderers must ensure rapid deployment under specific conditions (outbreak occurrence and HAEA consent).
EUR 16M
Valeur estimée
Durée
Catégorie
Critères d'attribution
Date limite
Détails des critères
Please consult the procurement documents.
Codes CPV supplémentaires
Note sur la valeur
Afficher les données TED originales
Description TED originale
This call for tenders aims to ensure clinical trial preparedness for Filovirus outbreaks through the establishment of an EU-based reserve of investigational vaccines as a critical preparedness measure, given the sporadic yet high-consequence nature of these pathogens. Specifically, the call aims to establish, pilot and maintain an investigational reserve of Filovirus candidate vaccines against Ebola Sudan (SUDV), Ebola Bundibugyo (BDBV) and/or Marburg (MARV), which – in case of an outbreak – could be used to advance their development by embedding them in outbreak-associated clinical trials, facilitated through international agreements and frameworks to support such preparedness. These provisions will allow for the rapid deployment of candidate vaccines for their later-stage development. Tenderers will further have to ensure the rapid deployment of the investigational doses, subject to specific conditions being met (such as the occurrence of an outbreak and the expressed consent of the Contracting Authority).
Détails de la procédure
- Date de publication
- 02 Jun 2026
- Langues
- English, Bulgarian
Métadonnées de référence
- Base juridique
- 32024R2509
Identifiants de référence
- ID de l'appel d'offres
- 381062-2026
Documents (2)
Appels d'offres similaires
Latvia – Experimental development services – Bakteriofāgu produktu izstrādes pakalpojums
Sweden – Experimental development services – Konsulter inom processkemi och uppskalning samt organisk- eller oorganisk kemi
Norway – Research services – Openness and inclusion - police interaction with the entire population
Score d'opportunité
Pourquoi ce score ?
Opportunité
70 / 100
Complexité
65 / 100
Facteurs de risque
Rapid deployment of investigational vaccines during outbreaks requires pre-established logistics, regulatory approvals...
Investigational vaccines are subject to evolving EU and international regulations. Changes in clinical trial or manufac...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications